Emergent BioSolutions (EBS) Tops Q2 EPS by $1.30, Raises Guidance

Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $1.98, $1.30 better than the analyst estimate of $0.68. Revenue for the quarter came in at $394.7 million versus the consensus estimate of $294.73 million.

GUIDANCE:

Emergent BioSolutions sees Q3 2020 revenue of $420-450 million, versus the consensus of $420.2 million.

Emergent BioSolutions sees FY2020 revenue of $1.5-1.6 billion, versus the consensus of $1.39 billion.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
• GitLab updates consumption revenue metric, CRR surpasses $20M
• Eli Lilly (LLY) PT Raised to $1,370 at Truist Securities